Edition:
United States

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

19.06USD
20 Jul 2018
Change (% chg)

$-0.20 (-1.04%)
Prev Close
$19.26
Open
$19.19
Day's High
$19.35
Day's Low
$18.70
Volume
245,691
Avg. Vol
308,997
52-wk High
$22.28
52-wk Low
$11.12

Chart for

About

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $648.11
Shares Outstanding(Mil.): 32.70
Dividend: --
Yield (%): --

Financials

  CARA.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -0.82 -- --
ROI: -51.22 -3.67 13.17
ROE: -52.83 -5.61 15.10

Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge

Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.

May 23 2018

BRIEF-Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement

* CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS

May 23 2018

BRIEF-Vifor Pharma: VFMCRP And Cara Therapeutics To Develop And Commercialise CR845 Injection For Chronic Kidney Disease-Associated Pruritus

* VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 23 2018

BRIEF-Cara Therapeutics Reports Q1 Loss Per Share $0.51

* CARA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Cara Therapeutics Reports Q4 Loss Per Share $0.43

* CARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

Earnings vs. Estimates